Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02748122 · ClinicalTrials.gov registry record · NA
CSII Pilot in Adolescents With Type 2 Diabetes
A NA study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02748122 is a NA study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 6 participants.
The verdict
NCT02748122, a NA study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
This feasibility pilot is intended to understand whether adolescents with Type 2 Diabetes (2DM) can be transitioned to a continuous subcutaneous insulin injection (CSII) and if so, assess whether CSII is a feasible treatment modality and improves quality of life (QOL) in adolescents with T2DM over 3 month period.
Interventions
- OTHER MMT 723
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-03-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02748122
The ClinicalTrials.gov registry entry for NCT02748122 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MMT 723 is the first listed.
NCT02748122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02748122 about?
NCT02748122 is a clinical study titled "CSII Pilot in Adolescents With Type 2 Diabetes". This feasibility pilot is intended to understand whether adolescents with Type 2 Diabetes (2DM) can be transitioned to a continuous subcutaneous insulin injection (CSII) and if so, assess whether CSII is a feasible treatment modality and improves quality of life (QOL) in adolescents with T2DM over 3...
What is the current status of trial NCT02748122?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2015-10. Estimated completion is 2019-03-27.
What interventions are being tested in trial NCT02748122?
The interventions under investigation include: MMT 723 (OTHER).
Who is sponsoring clinical trial NCT02748122?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.